Search results for "Fracture risk"
Testosterone may not decrease fracture risk in hypogonadism
A substudy of an industry-funded randomized trial in men with hypogonadism found that 3.50% of those assigned to testosterone and 2.46% assigned to placebo had a clinical fracture after 3.19 years of follow-up.
https://immattersacp.org/weekly/archives/2024/01/23/2.htm
23 Jan 2024
Closing the gap on osteoporosis
A new clinical guideline from ACP focuses on pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults.
https://immattersacp.org/archives/2023/05/closing-the-gap-on-osteoporosis.htm
1 May 2023
Atypical femur fracture risk increases with longer bisphosphonate use, drops after discontinuation
Researchers studied women ages 50 years or older who took bisphosphonates and were enrolled in the Kaiser Permanente Southern California health care system.
https://immattersacp.org/weekly/archives/2020/08/25/3.htm
25 Aug 2020
Vitamin D did not lower fracture risk in generally healthy patients, study finds
A new analysis of a large trial found no difference in total fractures, nonvertebral fractures, or hip fractures by whether men 50 years of age or older and women 55 years of age or older were randomized to vitamin D or placebo.
https://immattersacp.org/weekly/archives/2022/08/02/1.htm
2 Aug 2022
Act early to counter rise in osteoporosis
Recent studies indicate that late-life bone resiliency has been eroding, and newly released guidelines suggest diagnostic and treatment strategies to counteract that slide among women.
https://immattersacp.org/archives/2017/01/osteoporosis-care.htm
1 Jan 2017
Bisphosphonates associated with lower fracture risk, not associated with mortality
Lower mortality rates linked to bisphosphonates in previous observational studies might be due to direct biological effects of treatment, authors of a recent meta-analysis noted.
https://immattersacp.org/weekly/archives/2019/08/27/4.htm
27 Aug 2019
Guideline recommends pharmacologic treatment of osteoporosis in postmenopausal women at high fracture risk
Bisphosphonates are recommended for initial treatment, although ibandronate is not recommended for reducing nonvertebral or hip fracture risk, the clinical practice guideline from the Endocrine Society stated.
https://immattersacp.org/weekly/archives/2019/04/02/4.htm
2 Apr 2019
Correcting medicine's use of race in clinical algorithms
Recent efforts have pushed institutions to reconsider the use of race not just in estimating kidney function, but in a variety of algorithms and scores.
https://immattersacp.org/archives/2021/05/correcting-medicines-use-of-race-in-clinical-algorithms.htm
1 May 2021
Traumatic fractures associated with subsequent fracture risk in postmenopausal women
Data from the Women's Health Initiative suggest that either a high-trauma or low-trauma fracture warrants evaluation for osteoporosis and counseling about fracture risk.
https://immattersacp.org/weekly/archives/2021/06/15/4.htm
15 Jun 2021
Muscle relaxants compared for fall risk in older patients
Among new users ages 65 years and older, baclofen was associated with a higher risk of fall compared to tizanidine but no significant increase in risk versus cyclobenzaprine, a study found.
https://immattersacp.org/weekly/archives/2023/11/14/2.htm
14 Nov 2023